Public health authorities in Guinea-Bissau suspended a U.S.-funded hepatitis B vaccine study amid questions regarding the authority over clinical research conducted in Africa. The announcement was made at a press conference held today by officials from Guinea-Bissau's Ministry of Health, stating that the study is suspended pending a technical and ethical review by the country's national public health institute.
The decision follows weeks of conflicting statements regarding the trial's continuation. "There has been no sufficient coordination in order to take a final decision regarding the study," said Quinhin Nantote, the Minister of Public Health for Guinea-Bissau. "Faced with this situation, we decided to suspend it."
The meeting, convened by the Africa Centres for Disease Control and Prevention (Africa CDC), occurred after an official with the organization signaled last week that the trial would not proceed. The study aimed to evaluate a new approach to Hepatitis B vaccination. Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. The standard preventative measure is a vaccine, typically administered in a series of shots. The specifics of the U.S.-funded trial, including the exact vaccine being tested and the proposed vaccination schedule, have not been fully disclosed.
The suspension raises broader questions about the ethics and oversight of clinical trials conducted in Africa, particularly those funded by foreign entities. Some African scientists have voiced concerns about the extent to which local researchers and communities are involved in the design and implementation of such studies. These concerns often center on ensuring that research priorities align with the specific health needs of the African population and that there is adequate capacity building within African institutions to conduct and oversee clinical research independently.
Guinea-Bissau plans to implement a universal birth-dose policy for the Hepatitis B vaccine in 2027. The suspension of the trial will likely delay any potential integration of findings into this planned national program. The technical and ethical review by the national public health institute will determine the future of the study and address the concerns raised by African scientists.
Discussion
AI Experts & Community
Be the first to comment